e12602 Background: Chemotherapy is an important treatment strategy for breast cancer. Catheter related thrombosis (CRT) is one of the most common complications of catheterization, affecting patients’ living quality and survival. It is thus of great practical significance for exploring how to prevent CRT. That’s why we carried out this study to provide evidence-based medical data for the prevention and treatment of thrombosis in breast cancer patients. Methods: A prospective cohort study approach was adopted. Breast cancer patients who received deep vein catheterization chemotherapy from July 2021 to July 2023 were selected. Cohort A included patients in the treatment group: they received prophylactic anticoagulation after catheterization: Rivaroxaban, 10 mg, orally once/d for 2 months; cohort B included patients in the control group, who did not receive prophylactic anticoagulation. The thrombosis was compared between the patients in the two groups within six months after catheterization. The comparison between groups was tested by X 2 test, and logistic regression analysis was used to analyze the influencing factors of CRT. Results: A total of 402 breast cancer patients were enrolled. The incidence of CRT was 2.0% (4/201) in the treatment group of 201 cases and 12.4% (25/201) in the control group of 201 cases ( P=0.000). The thrombus was mainly located around the axillary vein, basilic vein and subclavian vein, the innominate vein, and the internal jugular vein. There were 44.8% (13/29) patients developed CRT within 30 days after catheterization, 20.7% (6/29) patients developed CRT within 30~<60days, and 34.5% (10/29) patients developed CRT within 60~<120 days. Patients diagnosed with CRT received anticoagulant therapy for 3 months. Within three months, the thrombus regression rate reached 100.0% (29/29). Univariate analysis showed that whether to receive prophylactic anticoagulation, whether hemoglobin is normal, patients whether to experience previous endocrine therapy, different Age group and chemotherapy regimens were actors for thrombosis, P<0.05 respectively. Multivariate analysis indicated that age and whether to receive prophylactic anticoagulation were independent factors for thrombosis ( P=0.019, P=0.006, respectively). Patients diagnosed with CRT received deep vein cannulation while anticoagulation therapy was administered, with smooth infusion. They all completed antitumor therapy as planned, and no abnormalities such as new thrombosis and pulmonary embolism were found. Conclusions: The prophylactic anticoagulation regimen with Rivaroxaban can reduce the incidence of CRT in breast cancer, showing good efficacy and safety. Therefore, medical staff should carry out early prevention, early detection and early treatment for CRT to improve the living quality of patients. Clinical trial information: ChiCTR2000031649.
Two new lignan glycosides, ussuriensislignan A (1) and ussuriensislignan B (2), together with seventeen known compounds (3–19), were isolated from the fruits of Pyrus ussuriensis. Their structures were determined by various spectroscopic methods. This is the first report of the isolation of lignans (compounds 1–3) from the genus Pyrus, and compounds 3–6, 12–16 were reported from Pyrus for the first time.
Abstract A chemical investigation of the roots of Pteroxygonum giraldii led to the isolation of a new arborane‐type triterpene, pteroxygonumnol A ( 1 ), a new myricetin glycoside, myricetin 3‐ O ‐ β ‐ D ‐galactopyranoside 3′‐ O ‐ β ‐ D ‐xylopyranoside ( 2 ), and a group of phenolic lipids, 3 – 6 , along with four known phenolic compounds, (−)‐epigallocatechin, (−)‐epigallocatechin gallate, gallic acid, and 2‐(4‐hydroxyphenyl)acetic acid. Their structures were elucidated on the basis of extensive spectroscopic analyses.
Abstract Five steroidal saponins, namely henryiosides A–E ( 1 – 5 ), were isolated from the EtOH extract of the rhizomes of Smilacina henryi. Their structures were elucidated by the extensive use of 1D‐ and 2D‐NMR experiments, along with HR‐MALDI‐MS analysis and the results of acid hydrolysis. The aglycones of henryiosides A–E possess a C(7)C(8) or C(9)C(11) bond and were not previously found in saponins.
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)